Algae power: could this supplement keep your brain young?
NCT ID NCT07379437
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether astaxanthin, a natural substance from algae, can slow brain aging in adults aged 50 and older. Over 6 months, 120 participants will take either a low or high dose of astaxanthin or a placebo. Researchers will measure changes in memory, thinking, brain scans, and blood markers to see if the supplement improves mitochondrial function and reduces oxidative stress.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Astaxanthin (from Haematococcus pluvialis algae)
- What this could lead to
- If it works, this could point toward a simple dietary supplement to help maintain cognitive function in older adults.
- What could go wrong
- This is an early-stage trial with only 120 people, so results may not apply to everyone. The supplement may show no benefit over placebo.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 120 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
May 2026
An estimate. Start dates often move.
- Expected to finish
-
Feb 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
50 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: Cognitive functionally normal elderly individuals aged 50 years or older with baseline MoCA scores near the borderline for mild cognitive impairment (MCI); subjects reporting age-related forgetfulness; community-dwelling residents who can cooperate with the research team to complete the intervention study. Exclusion Criteria: Individuals with hearing or language expression impairments that hinder communication; those with severe cardiovascular, cerebrovascular, hepatic, renal, or other organ diseases, or malignant tumors; individuals who have been taking astaxanthin or other antioxidant dietary supplements within the past month; those who have recently used medications that may affect neurological function; and individuals who are unable to undergo cognitive function assessment or refuse to sign an informed consent form.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Brain aging are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- AI plus ultrasound could catch heart and lung decline before it turns critical
- Can a dead probiotic revive aging brains?
- A new kind of MRI aims to watch brain connections change in seconds
- Can flaxseed oil protect the aging brain? new trial targets APOE4 carriers
- Shining a light on brain aging: new study tests Non-Invasive therapy